Lyell Immunopharma (NASDAQ:LYEL) reported quarterly losses of $(1.10) per share which beat the analyst consensus estimate of $(2.19) by 49.77 percent. This is a 69.44 percent increase over losses of $(3.60) per share from the same period last year. The company reported quarterly sales of $2.000 thousand which missed the analyst consensus estimate of $4.400 thousand by 54.55 percent. This is a 71.43 percent decrease over sales of $7.000 thousand the same period last year.